Skip to main content

Advertisement

SpringerLink
Log in

Ustekinumab poised to enter the psoriasis market

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Centocor's mAb Stelara is the first dual-action drug aimed at the p40 subunit of the IL-12 and IL-23 cytokines to treat severe plaque psoriasis.

Author information

Authors and Affiliations

  1. Portland, Maine

    Charlie Schmidt

Authors
  1. Charlie Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, C. Ustekinumab poised to enter the psoriasis market. Nat Biotechnol 26, 1317–1318 (2008). https://doi.org/10.1038/nbt1208-1317a

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1208-1317a

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation